Review article · 29 Jan 2024
Conference abstractPublished 10 Aug 2015
Novel approaches to battle bacterial resistance
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The susceptibility and pharmacodynamic activity of ciprofloxacin & new fluoroquinolones was studied against low-level (MIC 4 ug/ml) and high-level (MIC 16 ug/ml) ciprofloxacin-resistant Streptococcus pneumoniae. An in vitro pharmacodynamic model simulating free fluoroquinolone (protein unbound) serum concentrations using Cpmax & AUC0-24h achieved after standard oral doses for community acquired respiratory infections was used to compare bacterial killing by 5 fluoroquinolones. Against 6 ciprofloxacin-resistant S. pneumoniae isolates (4 different resistance mutant phenotypes; ParC, efflux, ParC with efflux & ParC & GyrA) obtained from an ongoing Canadian respiratory organism surveillance study. The potency (MIC only) of fluoroquinolones was gemifloxacin>moxifloxacin>gatifloxacin>levofloxacin> ciprofloxacin. Ciprofloxacin (free AUC 0-24h/ MIC 0.9-3.5) produced no reduction of growth at 6, 24 or 48 hours compared to the initial inoculum against all six strains. Levofloxacin (free AUC 0-24h/MIC 35) was bactericidal (≥3 log10 killing) at 6, 24 and 48 hours for the ParC as well as the efflux mutants, but only bactericidal at 24 hours for the ParC with efflux strain. Levofloxacin (free AUC 0-24h/MIC 4.4) demonstrated no reduction of growth relative to the initial inoculum against the ParC and GyrA mutants. Gatifloxacin and moxifloxacin (free AUC 0-24h/MIC of 48 and 60, respectively) were bactericidal at 6, 24 and 48 hours against the ParC, efflux and ParC with efflux mutants, but demonstrated little to no growth reduction (free AUC 0-24h/MIC of 6 and 7.5, respectively) against ParC and GyrA mutants. Gemifloxacin (free AUC24/MIC 67-133) was bactericidal (≥3 log10 killing) at 6, 24 and 48 hours against all low-level ciprofloxacin-resistant S. pneumoniae mutants. Against 2 of the ParC and GyrA mutants gemifloxacin (free AUC 0-24h/MIC of 32) was bactericidal at 6, 24 and 48 hours but against one ParC and GyrA mutant (free AUC 0-24h/MIC of 16) gemifloxacin demonstrated reduced activity with initial killing at 24 hours but with subsequent regrowth. These data suggest that ciprofloxacin produces no inhibition in growth against low or high level ciprofloxacin-resistant S. pneumoniae, while gatifloxacin, levofloxacin and moxifloxacin (moxi>gati>levo) were bactericidal against low-level resistant strains but produced little to no inhibition vs. high-level resistant strains. Gemifloxacin when simulating free AUC0-24h/MIC ≥32 was bactericidal against low and high level resistant strains. When simulated free AUC0-24h/MIC was ≥16 gemifloxacin allowed regrowth of high-level ciprofloxacin-resistant strains.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Perspective · 25 Nov 2024
Antiviral Resistance in Influenza: Challenges and Novel Therapeutic Approaches
Article · 28 Aug 2024
Emerging Therapies for Treatment-Resistant Depression: A Review of Novel Pharmacological and Neuromodulation Approaches
Opinion · 30 Nov 2023
Antimicrobial Resistance: Novel Approaches to Combat the Growing Threat of Drug-Resistant Microorganisms
Short communication · Sep 2020
Bacteriophages: A novel approach of treating multidrug resistant bacteria present in hospital wastewater
More from this journal
The newest in Journal of Pharmaceutical Care & Health Systems.
Review article · 9 Jun 2025
Blood Fluid: The Unseen Currents That Bind Life and Death Together
Research article · 8 Jun 2025
Formulation and Antibacterial Evaluation of Acmella olaracea (Akarkara) Gummies Used for Toothache
Research article · 9 Apr 2025
Deep Vein Thrombosis: A Closer Look at a Silent Threat
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutical Care & Health Systems
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ayman Noreddin”

